Fengguang Guo is a scientist at CTMC, a joint venture between Resilience and MD Anderson Cancer Center, since November 2022, focusing on the development of SpectroFlow panels to characterize immune cells. Previously, Guo served as an Associate Research Scientist at Texas A&M Health Science Center, leading projects to engineer bacteria for cancer treatment enhancement and held a Postdoctoral Research Associate position where multiple multidisciplinary projects were managed. Prior roles include Postdoctoral Fellow at Texas A&M University College of Veterinary Medicine & Biomedical Sciences, where a high-throughput screening method for anti-microbial drugs was developed, and a Graduate Student Research Associate at Texas A&M University specializing in lipid metabolic pathways in Cryptosporidium parvum. Guo's early career included positions as a Project Specialist and Lab Manager at DBN Agricultural Science and Technology Institute. Educational credentials include a Ph.D. in Veterinary Microbiology from Texas A&M College of Veterinary Medicine & Biomedical Sciences and degrees in Plant Pathology and a Bachelor of Science from universities in China.
This person is not in any offices
CTMC / A joint venture between Resilience + MD Anderson Cancer Center
Cell Therapy Manufacturing Center (CTMC) is a joint venture between Resilience and MD Anderson Cancer Center. CTMC was created to bring together the leading complex biologics manufacturing technology organization and the #1 clinical cancer center to enable innovation from academia and biotech to accelerate Cell Therapy’s impact for cancer patients.
Employees
51-200